Congestive Heart Failure and Colostrum

  • warning: Illegal string offset 'data' in /home/immun459/public_html/includes/tablesort.inc on line 110.
  • warning: Illegal string offset 'data' in /home/immun459/public_html/includes/tablesort.inc on line 110.

Colostrum and Congestive Heart Failure

Dear consumer,

Your inquiry regarding the use of high quality bovine colostrum inassociation with congestive heart failure has been forwarded to me. I ama business and technology consultant with extensive knowledge regarding the formation andcomposition of bovine colostrum and its health-related applications in humans and animals.Congestive heart failure is a multiple etiology, high prevalence, poor prognosis disorder.Medical treatment of dilated cardiomyopathy is aimed at alleviating acute heart failure.Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) are involved in manyphysiological aspects, including the control of muscle mass and function, body composition andregulation of metabolism. The roles of GH and IGF-1 as modulators of myocardial structure hasbeen well established (see references listed below). Receptors for both GH and IGF-1 areexpressed by cardiac tissues and, therefore, it is highly likely that GH may act directly on theheart, whereas IGF-1 may act by endocrine, paracrine or autocrine mechanisms. Animal modelsof pressure and volume overload have demonstrated reduction of cardiac IGF-1 production andexpression of GH and IGF-1 receptors, implying that regulation of these factors is influenced byhemodynamic changes. Moreover, studies suggest that GH and IGF-1 have stimulatory effectson myocardial cells, possibly mediated by intracellular calcium handling. It has been shown thatadministration of GH can induce an improved hemodynamic and clinical status in some patients.Complete first milking bovine colostrum, which is the basis of all products sold by Immune-Tree, is an excellent resource for both GH and IGF-1 providing that the colostrum used isproperly processed to retain the bioactivity of its components. In humans, many of thesubstances necessary for development and survival of the fetus are transferred across theplacental barrier. In sharp contrast, in bovines none of the substances necessary for developmentor to afford interim protection against pathogens are transferred across the placenta. In order toreceive an adequate quantity of these substances, the calf must either nurse extensively duringthe first 8-10 hours after being born or be hand-fed at least 2 quarts of colostrum. As such,bovine colostrum is a rich resource of many biologically-active substances that have been shownto be safe and effective for humans.

Studies recently completed at a major Endocrinology Diagnostic Laboratory clearlydemonstrated that the colostrum products from Immune-Tree contain a significant quantity ofIGF-1 and that the amount present is substantially greater than that found in competitor products.It is very, very important to recognize that all colostrum products are not the same and, despitethe claims made by their manufacturers, they do not all contain every beneficial component at anoptimum concentration and, in many cases, they have been manipulated and may be missingsome of the essential components. When choosing a colostrum product, you should be certainthat it is made from only first milking bovine colostrum collected within 8-10 hours after birth ofthe calf and that the colostrum is "complete" and that none of the components have beenremoved, including the fat.

References:

Conti E, et al, Markedly reduced insulin-like growth factor-1 in acute phase myocardial infarction. J Am CollCardiol 38(1):26-32, 2001Ueda H, et al, A potential cardioprotective role of hepatocyte growth factor in infarction in rats. Cardiovasc Res51(1):4-6, 2001Palmen M, et al, Cardiac remodeling after myocardial infarction is impaired in mice. Cardiovasc Res 50(3):516-24,2001Loennechen JP, et al, Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in infarcted rat heart.Am J Physiol Heart Circ Physiol 280(6):H2902-10, 2001Vaessen N, et al, A polymorphism in the gene for IGF-1: functional properties and type 2 diabetes and myocardialinfarction. Diabetes 50(3):637-42, 2001Colao A, et al, Growth hormone and the heart. Clin Endocrinol 54(2):137-54, 2001Yamamura T, et al, IGF-1 differentially regulates Bcl-xL and Bax and confers myocardial protection in the rat heart.Am J Physiol Heart Circ Physiol 280(3):H1191-H1200, 2001Bocchi EA, et al, Growth hormone for optimization of refractory heart failure treatment. Arq Bras Cardiol73(4):391-8, 1999Volterrani M, et al, Role of growth hormone in chronic heart failure: therapeutic implications. Ital Heart J1(11):732-8, 2000Omerovic E, et al. Growth hormone improves bioenergetics and decrease catecholamines in postinfarct rat hearts.Endocrinology 141(12):4592-99, 2000Broglio F, et al, Normal IGF-1 and enhanced IGFBP-3 response to very low rhGH doses in patients with dilatedcardiomyopathy. J Endocrinol Invest 23(8):520-5, 2000Schnabel P, et al, Hormone therapy in heart failure: growth hormone and insulin-like growth factor-1. Z Kardiol88(1):1-9. 1999Ross J, Ryoke T, Effects of growth hormone and insulin-like growth factor-1 in experimental heart failure. GrowthHorm IGF Res 8(4):167-70, 1998Osterziel KJ, et al, The somatotrophic system in patients with dilated cardiomyopathy: insulin-like growth factor-1and its alterations during growth hormone changes to cardiac function. Clin Endocrinol 53(1):61-8, 2000Donath MY, Zapf J, Insulin-like growth factor-1: an attractive option for chronic heart failure. Drugs Aging15(4):251-4, 1999Houck WV, et al, Effects of growth hormone supplementation on left ventricular myocardial and myocycte functionwith the development of congestive heart failure. Circulation 100(19):2003-9, 1999Lee WL, et al, Insulin-like growth factor-1 improves cardiovascular function and apoptosis of cardiomyocytes indilated cardiomyopathy. Endocrinology 140(10):4831-40, 1999Broglio F, et al, Activity of GH/IGF-1 axis in patients with dilated cardiomyopathy, Clin Endocrinol 50(4):417-30, 1999Giustina A, et al, Endocrine predictors of acute hemodynamic effects of growth hormone in congestive heart failure.Am Heart J 137(6):1035-43, 1999Isgaard J et al, The role of the GH/IGF-1 axis for cardiac function and structure. Horm Metab Res 30(2-3): 50-54,1999

To your good health - always.

Sincerely,

Alfred E. Fox, Ph.D.

Dr. Alfred E. Fox holds a Ph.D. from Rutgers University in Microbiology (Immunochemistry)and has more than 25 years of senior management experience at Carter-Wallace, Baxter DadeDivision and Warner-Lambert, where he was responsible for research and development andregulatory affairs. He was also the founder and president of two biotechnology companiesfocused on agribusiness and environmental monitoring, respectively. For the past 15 years, Dr.Fox has been the President of Fox Associates, a business and technology consulting firm servingsmall- to mid-size companies in the human and animal healthcare fields. He focuses primarilyon marketing and regulatory issues and for the past 10 years has continuously consulted tobovine colostrum manufacturers, where he has gained regulatory approval for their products,been a technical advisor, helped design and develop marketing strategies and served as anexpert witness in legal matters.

AttachmentSize
Congestive Heart Failure and Colostrum.pdf910.48 KB
Copyright © 2001 Avinaut International CC

Tel:  +2711-869-2945 Fax:  +2711-869-2952 Cell: +2783-268-9126

Microplanet | Log In | Website Hosting by: New Beginnings Web & Marketing Solutions

Immunetree SA, Colostrum specialists.